| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3880292 | The Journal of Urology | 2006 | 6 Pages |
Abstract
WX-G250 combined with LD-IL-2 in patients with metastatic RCC is safe and well tolerated. With a substantial clinical benefit and a median survival of 22 months in patients with metastatic RCC who have progressive disease at study entry combination therapy showed increased overall survival compared to WX-G250 monotherapy. Survival was at least similar to that of currently used cytokine regimens but with a favorable toxicity profile.
Keywords
5FURCCPBMCSAEADCCCA-IXmRCCIL-2natural killerHacAantibody dependent cellular cytotoxicityimmunotherapyIFNInterferon-αInterleukin-2stable diseaseprogressive diseasecomputerized tomographyBayPeripheral blood mononuclear cellCytokinesSerious adverse eventVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)5-fluorouracilNeoplasm metastasisMiuKidney neoplasmslytic unitsPartial responsecomplete responseRenal cell carcinomaMetastatic renal cell carcinomaCarbonic anhydrase IXKidneyLymph node
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
I. Bleumer, E. Oosterwijk, J.C. Oosterwijk-Wakka, M.C.W. Völler, S. Melchior, S.O. Warnaar, C. Mala, J. Beck, P.F.A. Mulders,